Clinical trial
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
Name
ARGX-113-2011
Description
The purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with IIM who previously participated in ARGX-113-2007. Secondary objectives include efficacy measures of efgartigimod PH20 SC in participants with IIM.
Trial arms
Trial start
2023-09-12
Estimated PCD
2027-09-01
Trial end
2027-09-01
Status
Recruiting
Phase
Early phase I
Treatment
EFG PH20 SC
Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
Arms:
EFG PH20 SC
Size
240
Primary endpoint
Incidence treatment-emergent adverse events and adverse event of special interest
Up to 60 weeks
Eligibility criteria
Inclusion Criteria:
* Has completed trial ARGX-113-2007
* Being capable of providing signed informed consent and complying with protocol requirements
* Agrees to use contraceptive measures consistent with local regulations and women of childbearing potential must have a negative urine pregnancy test at baseline before receiving the investigational medicinal product
Exclusion Criteria:
* Intention to have major surgery during the study period; or any other medical condition that has arisen since enrollment in study ARGX-113-2007, that in the investigator's opinion, would confound the results of the study or put the participant at undue risk
* Known hypersensitivity reaction to investigational medicinal product or 1 of its excipients Development of any malignancy, either new or recurrent, other than basal cell carcinoma of the skin, regardless of relatedness
* Permanent discontinuation of IMP in ARGX-113-2007, or met the permanent discontinuation criteria at the rollover visit
* Diagnosis with a deselected subtype of myositis based on the analysis of the phase 2 stage data in ARGX-113-2007, unless the investigator determines that the participant is benefiting from IMP as defined by a score of "much better" or "moderately better" on the 'Clinical Global Impression of Change' and 'Patient Global
* Impression of Change' assessments for at least 12 weeks, and that enrolling in the study is in the participant's best interest
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 240, 'type': 'ESTIMATED'}}
Updated at
2024-04-08
1 organization
2 products
6 indications
Product
EFG PH20Indication
MyositisIndication
Idiopathic Inflammatory MyopathyIndication
DermatomyositisIndication
polymyositisIndication
Immune-Mediated Necrotizing MyopathyIndication
Antisynthetase SyndromeOrganization
ArgenxProduct
EFG PH20 SC